Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Healthtrust
AstraZeneca
Novartis
Citi
Accenture
Teva
Chubb
Mallinckrodt

Generated: October 20, 2017

DrugPatentWatch Database Preview

BESIVANCE Drug Profile

« Back to Dashboard

What is the patent landscape for Besivance, and when can generic versions of Besivance launch?

Besivance is a drug marketed by Bausch And Lomb and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-three patent family members in nineteen countries.

The generic ingredient in BESIVANCE is besifloxacin hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the besifloxacin hydrochloride profile page.

Summary for Tradename: BESIVANCE

US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list27
Clinical Trials: see list12
Patent Applications: see list13
Drug Prices:see details
DailyMed Link:BESIVANCE at DailyMed

Pharmacology for Tradename: BESIVANCE

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: BESIVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: BESIVANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,970Topical treatment of prevention of ocular infections► Subscribe
6,239,113 Topical treatment or prevention of ocular infections► Subscribe
7,056,893Topical treatment for prevention of ocular infections► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
6,569,443 Topical treatment or prevention of ocular infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BESIVANCE

Country Document Number Estimated Expiration
European Patent Office1588702► Subscribe
Hong Kong1137947► Subscribe
South Korea20130010131► Subscribe
Argentina075926► Subscribe
Hong Kong1063721► Subscribe
Japan2010083901► Subscribe
Canada2756769► Subscribe
Japan4904621► Subscribe
World Intellectual Property Organization (WIPO)02100309► Subscribe
TaiwanI318878► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
US Department of Justice
Chinese Patent Office
McKesson
Merck
Johnson and Johnson
Accenture
McKinsey
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot